Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2XLHY)

Drug Name

N-benzyl-5-(4-chlorophenyl)nicotinamide Drug Info

Synonyms

CHEMBL1271417; N-benzyl-5-(4-chlorophenyl)nicotinamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[2]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[3]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[3]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[4]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[5]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[3]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[6]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[7]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[8]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5.
2	Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
5	Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
6	Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
9	Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.